1 Protocol NCT01502787 Title: Attenuation of Angiotensin II-Mediated Vasoconstriction in Hypertension with Nebivolol Investigators Name (printed) Deg Rank Phone Mail E-mail Code Wanpen Vongpatanasin M.D. Associat (214) 8586 Wanpen.Vongpatanasin@ (Principal Investigator and e Prof 648-7950 utsouthwestern.edu Faculty Sponsor) Gail Thomas PhD Associat (214) 8586
[email protected] (Sub-Investigator) e Prof 648-7950 Debbie Arbique R.N. Senior (214) 8586
[email protected] (Sub-Investigator) R.N. 648-2968 Ronald Victor MD Prof (214) 8586
[email protected] (Sub-Investigator) 648-7950 Participating Institutions: Univ. of Texas Southwestern Medical Center Funding: Forest Research Institute Table of Contents: Protocol Section Pages 1) Schema 2-3 2) Objectives 2 3) Background 4 4) Agent/Device 4-5 5) Eligibility criteria 6 6) Material and data to be accessioned 6-8 7) Treatment 8-9 8) Evaluation criteria 10 9) Off-study criteria 10 10) Registration and study monitoring 10-11 11) Statistical considerations 12 12) Gender/minority analysis 13 13) References 14-15 July 25, 2008 1 2 Objectives: The overall objective of this study is to determine if Nebivolol a) attenuates angiotensin II- induced increase in oxidative stress, thereby attenuating angiotensin II-induced vasoconstriction and blood pressure elevation and b) attenuates sympathetic mediated vasoconstriction during exercise, thereby reducing functional skeletal muscle ischemia in hypertensive patients. Schema In 25 untreated hypertensive subjects, we